Clinical trial
Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the…
NCT00353015 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00353015 |
|---|---|
| Title | Irinotecan and Cisplatin for High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract |
| Official title | A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Pharmacia Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Cancer, Carcinoma, Neuroendocrine |
| Intervention type | Drug |
| Interventions | Cisplatin, Irinotecan |
| Enrollment | 21 |
| Start date | Mar 1, 2003 |
| Primary completion | Dec 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Jul 17, 2006 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: